Skip to content
The Mumbai

Sun Pharma Inks Global Licensing Deal With LIB Therapeutics For PCSK9 Inhibitor

Sun Pharma Inks Global Licensing Deal With LIB Therapeutics For PCSK9 Inhibitor
Photo: Free Press Journal · view original

Mumbai: Sun Pharmaceutical Industries Limited on Monday announced a global licensing and commercialisation agreement with LIB Therapeutics Inc. for lerodalcibep, a PCSK9 inhibitor used to lower LDL-C. EU Approval and Market Lerodalcibep, branded Lyrokaul, received EU approval on 21 September 2026...

Sources and story details